Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Phase 3 Sickle Cell Disease Trials

5 Phase 3 trials for Sickle Cell Disease. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT06609226

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood...

Sponsor: Novo Nordisk A/SEnrolling: 48020 locations
RECRUITINGPhase 3NCT05392894

RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease

The purpose of this clinical trial is to evaluate the clinical and cost effectiveness of Haploidentical Stem Cell Transplantation (SCT) for adults with severe sickle cell disease...

Sponsor: King's College Hospital NHS TrustEnrolling: 1201 location
RECRUITINGPhase 3NCT05378555

Oral Ketamine for Treatment of Vaso-Occlusive Pain

The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to...

Sponsor: Boston Children's HospitalEnrolling: 101 location
RECRUITINGPhase 3NCT06975865

The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate...

Sponsor: SanofiEnrolling: 19220 locations
RECRUITINGPhase 3NCT05285917

Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa

Sickle cell anemia (SCA) is among the world's most common and devastating blood disorders, affecting more than 300,000 newborns per year. Most infants with SCA are born in the...

Sponsor: Brown UniversityEnrolling: 4001 location